Best Probiotic for Constipation and Gut Health in 2025 - Most Effective Probiotics for Bloating, Gas and Digestion
YourBiology
Glasgow, May 15, 2025 (GLOBE NEWSWIRE) --Dealing with bloating, gas, or frustrating constipation? You're not alone—gut health has become a top priority for so many of us.
The science says, overwhelmingly, that certain probiotics can make a huge difference, helping to ease chronic constipation and bowel movements, balance your microbiome, and get things moving smoothly again.
But with so many probiotic options out there, it's hard to know which strains are the most effective for bloating, gas and constipation.
That's why we've done the research for you. In this guide, we're breaking down the best probiotics for constipation and gut health in 2025—the ones that really help with bloating, gas, and overall digestion.
Whether you're looking for everyday gut support or relief from chronic digestive issues, these probiotics are here to help you feel your best. Let's get started!
Top Probiotic Supplement of 2025
YourBiology is the best choice for probiotics, offering a 60-day money-back guarantee and free shipping to the United States, Canada, Australia, and the UK, ensuring a risk-free and convenient way to improve your gut health.
> CLICK to view current special offers and discounts from YourBiology
CLICK to view more testimonials and success stories from YourBiology
CLICK to view pricing and current discounts from YourBiology CLICK to visit YourBiology official website <
Frequently Asked Questions About Probiotics for Constipation, Bloating, Gas, and IBS
How do probiotics help with constipation?
Probiotics improve digestion by balancing the gut microbiome. They increase the number of beneficial bacteria that aid in breaking down food and softening stools, promoting regular bowel movements. Certain strains like Bifidobacterium Lactis are particularly effective for relieving constipation by improving stool consistency and motility.
Can probiotics reduce bloating and gas?
Yes, probiotics can help reduce bloating and gas by balancing the gut bacteria and improving digestion. They reduce fermentation in the gut, which is a common cause of gas buildup and bloating. Strains like Lactobacillus Acidophilus and Lactobacillus Plantarum are known to ease these symptoms.
Which probiotic strains are best for IBS?
For Irritable Bowel Syndrome (IBS), strains like Bifidobacterium Lactis, Lactobacillus Acidophilus, and Bifidobacterium Longum are highly recommended. These strains alleviate IBS symptoms by reducing bloating, abdominal pain, and irregular bowel movements. They also help lower inflammation in the gut.
How long does it take for probiotics to work?
Most people notice improvements in bloating, gas, and constipation within 1-2 weeks of daily probiotic use. However, for chronic issues like IBS, it may take 4-6 weeks to see significant changes. Consistency is key for lasting benefits.
Can probiotics make constipation worse?
In rare cases, probiotics may initially cause mild bloating or gas as your gut adjusts to the new bacteria. These symptoms are temporary and usually resolve within a few days. Drinking plenty of water and starting with a lower dose can help.
Should I take probiotics daily?
Yes, taking probiotics daily is recommended to maintain a healthy balance of gut bacteria. Regular use supports ongoing digestion, prevents constipation, and reduces symptoms like bloating and gas.
Are probiotics safe for everyone?
Probiotics are generally safe for healthy adults. However, people with weakened immune systems, autoimmune diseases, or serious illnesses should consult a healthcare provider before using probiotics, as they may pose risks in rare cases.
Do probiotics help with stress-related IBS symptoms?
Yes, certain probiotics can help with stress-related IBS symptoms by supporting the gut-brain connection. Strains like Bifidobacterium Longum reduce inflammation and regulate the gut environment, which can alleviate symptoms triggered by stress.
Can I take probiotics with other medications?
Probiotics are generally safe to take with most medications, but timing can be important. For example, if you're on antibiotics, it's best to take probiotics a few hours apart to prevent the antibiotics from killing the beneficial bacteria. Always consult your doctor before combining supplements with medications.
Are there natural food sources of probiotics for gut health?
Yes, fermented foods like yogurt, kefir, sauerkraut, kimchi, and miso are rich in natural probiotics. These foods can help support gut health, but supplements often provide a higher concentration of beneficial bacteria for targeted relief from issues like constipation, bloating, and IBS.
By incorporating probiotics into your routine, you can target the root causes of digestive discomfort and improve your overall gut health.
Project name: YourBiologyAddress - WOLFSON BRANDS (UK) LIMITED, 12 Payne Street, Glasgow, G4 0LFUnited KingdomCompany website: https://yourbiology.com/Email: support@yourbiology.comContact - +1 888-708-6394Media Contact:Full Name - Tony Stevens
Attachment
YourBiology
CONTACT: Project name: YourBiology Address - WOLFSON BRANDS (UK) LIMITED, 12 Payne Street, Glasgow, G4 0LF United Kingdom Company website: https://yourbiology.com/ Email: support@yourbiology.com Contact - +1 888-708-6394
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
How Japan's Fast-Paced Lifestyle Fuels Adoption of Home-based Massage Chairs
Japan's Massage Chair Market offers opportunities driven by the aging population and rising wellness focus, with demand for therapeutic solutions growing. Technological innovations, like AI customization and eco-friendly materials, enhance appeal. However, competition from affordable alternatives presents a challenge. Japanese Massage Chair Market Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Japan Massage Chair Market, By Region, Competition, Forecast & Opportunities, 2020-2030F" has been added to Japanese Massage Chair Market was valued at USD 223.45 Million in 2024, and is expected to reach USD 345.67 Million by 2030, rising at a CAGR of 7.54%. This growth is driven by the country's aging population and an increasing focus on personal wellness and comfort. With a significant portion of the population aged 65 and older, demand for at-home therapeutic solutions like massage chairs is rising. Consumers are increasingly prioritizing health and relaxation, favoring products that alleviate stress, muscle pain, and fatigue. Technological advancements: including AI-based customization, zero-gravity features, and integrated health monitoring - are also expanding the market appeal. Moreover, Japan's fast-paced urban lifestyle and limited time for spa or clinic visits are accelerating the adoption of home-based wellness devices, positioning massage chairs as a practical and long-term investment in self-care. Key Market Drivers: Rising Elderly Population Across the Region The increasing elderly population in Japan is a key driver of the massage chair market. In 2023, the number of people aged 65 and over rose by 20,000, totaling 36.25 million. As aging brings common issues such as joint pain, poor circulation, and muscle stiffness, massage chairs offer an effective, convenient solution for daily physical relief and relaxation. These devices are non-invasive and user-friendly, providing an attractive alternative to regular therapy sessions. The inclusion of advanced features like body scanning, heat therapy, and air compression has made them even more suitable for senior users. As Japan continues to lead globally in aging demographics, the market for massage chairs is expected to grow steadily, supported by initiatives that promote senior health and comfort. Key Market Challenges: Increased Competition from Substitutes The massage chair market in Japan faces notable competition from alternative relaxation and therapeutic products such as handheld massagers, massage mats, and compact portable devices. These alternatives are often more affordable, space-efficient, and user-friendly, appealing especially to younger consumers or those with budget constraints. Furthermore, wellness practices like yoga, stretching, and meditation serve as non-mechanical ways to alleviate stress and physical discomfort, adding to the variety of consumer choices. As a result, manufacturers of massage chairs are under pressure to innovate and differentiate their products through superior technology and enhanced user experience. The growing popularity of multifunctional and tech-savvy wellness gadgets could potentially slow the adoption of traditional massage chairs, especially in densely populated urban settings where space optimization is a priority. Key Market Trends: Surging Popularity for Eco-Friendly Materials Sustainability is becoming a central trend in the Japanese massage chair market, driven by growing environmental awareness among consumers. Manufacturers are increasingly integrating eco-friendly materials like recycled plastics, sustainably sourced wood, and biodegradable fabrics into their product designs. In line with Japan's national commitment to net-zero emissions by 2050, energy-efficient technologies and recyclable product components are also being introduced. These efforts resonate with a rising segment of eco-conscious buyers and help brands differentiate themselves in a competitive landscape. As sustainability gains prominence in consumer decision-making, the adoption of green practices in manufacturing and packaging is expected to influence future product development and market positioning. Key Market Players: Fuji Medical Instruments Mfg. Co., Ltd. Panasonic Holdings Corporation Family Inada Co., Ltd Human Touch, LLC Daiwa Massage Cozzia-USA LLC VD GROUP Infinite Creative Enterprises, Inc. Massage Chair Heaven OSIM International Pte. Ltd Report Scope: In this report, the Japan Massage Chair Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: Japan Massage Chair Market, By Type: Conventional Robotic Japan Massage Chair Market, By Product Type: Inversion Massage Chairs Zero Gravity Massage Chairs Others Japan Massage Chair Market, By Distribution Channel: Online Offline Japan Massage Chair Market, By Region: Hokkaido & Tohoku Chubu Chugoku Kyushu Rest of Japan Key Attributes: Report Attribute Details No. of Pages 82 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $223.45 Million Forecasted Market Value (USD) by 2030 $345.67 Million Compound Annual Growth Rate 7.5% Regions Covered Japan For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Japanese Massage Chair Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
31 minutes ago
- Yahoo
ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress
ZYNLONTA® in combination with glofitamab (COLUMVI®) in patients with r/r DLBCL demonstrated clinically meaningful benefit with overall response rate (ORR) of 93.3% and a complete response (CR) rate of 86.7% across 30 efficacy evaluable patients 25 of 26 patients achieving CR remained in CR as of the data cut-off Initial data show the combination is generally well tolerated with a manageable safety profile Company expanding enrollment for LOTIS-7 to 100 patients at 150 µg/kg dose Company to host conference call today at 8:00 a.m. ET/2:00 p.m. CEST LAUSANNE, Switzerland, June 12, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) to be presented at the European Hematology Association 2025 Congress (EHA2025) in Milan, Italy. The Company will host a conference call and webcast featuring LOTIS-7 trial principal investigator and EHA presenting author, Juan Alderuccio, MD, Clinical Site Disease Group Leader, Lymphoma Section, at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine today at 8:00 a.m. ET to discuss the results. To access the conference call, please register here. "The data seen in this study with the combination of ZYNLONTA and glofitamab has shown a manageable safety profile along with strong efficacy data from patients with relapsed or refractory DLBCL, with complete responses observed regardless of prior therapy, including CAR-T," said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics. "The combination of these two anti-cancer agents holds significant promise for advancing the treatment landscape and addressing unmet need in patients with these hard-to-treat lymphomas." The presentation highlights updated data as of April 14, 2025, in which r/r LBCL patients received dose levels of 120 µg/kg or 150 µg/kg of ZYNLONTA plus the bispecific antibody glofitamab, with 41 patients evaluable for safety and 30 patients evaluable for efficacy. Key highlights of the LOTIS-7 data presentation are as follows: Best overall response data among the 30 efficacy evaluable patients shows overall response rate (ORR) of 93.3% (28/30 pts) as assessed by Lugano Criteria Complete response (CR) rate of 86.7% (26/30 pts) Of these, 25/26 patients achieving CR remain in CR as of the data cut-off Median time to CR in 120 µg/kg = 80 days Median time to CR in 150 µg/kg = 42 days 12 patients converted from stable disease (SD) or partial response (PR) to CR over time (1 and 11 pts respectively) Of the 6 patients previously treated with CAR-T and undergoing response assessment, 5 achieved a CR Among the 41 safety evaluable patients, the combination was generally well tolerated with a manageable safety profile and no DLTs across dose levels Grade 3 or higher treatment emergent adverse events (TEAEs) observed in > 5% of patients included neutropenia (24.4%), anemia (9.8%), AST increased (7.3%), GGT increased (7.3%), and thrombocytopenia (7.3%) In the 150 µg/kg dose, cytokine release syndrome (CRS) (23.8%), all of which were Grade 1, and immune effector cell-associated neurotoxicity syndrome (ICANS) (4.8%), with one case of Grade 2, were observed In the 120 µg/kg dose, CRS all grades (55%), all of which were Grade 1/2 except one case of Grade 3, and ICANS (10%), with one case of Grade 1 and one case of Grade 2, were observed TEAEs leading to discontinuation included 3 each for ZYNLONTA and glofitamab There were no Grade 5 TEAEs observed "We believe these new data are differentiating and further reinforce the potential of ZYNLONTA plus the bispecific glofitamab to improve outcomes for DLBCL patients who need it most," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. "This early safety and efficacy data support the ongoing expansion of this study to 100 patients at the 150 µg/kg dose of ZYNLONTA plus glofitamab. We look forward to discussing the results with Dr. Alderuccio during our conference call today in addition to the presentation of the data set across two key conferences." This data will be shared at EHA2025 during a poster presentation on June 14 at 6:30 p.m. CEST and also as an oral encore presentation at the 18th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland on Friday, June 20 at 9:00 a.m. ET. The Company plans to share additional data before the end of 2025. Conference Call InformationTo access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the ADC Therapeutics website at The archived webcast will be available for 30 days following the call. About LOTIS-7LOTIS-7 is a Phase 1b global multicenter, multi-arm study in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) including Part 1 (dose escalation) and Part 2 (dose expansion). The three dosing arms include ZYNLONTA plus polatuzumab vedotin, ZYNLONTA plus glofitamab, and ZYNLONTA plus mosunetuzumab T-cell-engaging bispecific monoclonal antibodies (BsAbs). Enrollment in LOTIS-7 includes Part 1 of the study with a 3+3 dose escalation in 3L/3L+ heavily pre-treated patients with ZYNLONTA doses starting at 90 µg/kg and then proceeding to 120 µg/kg and 150 µg/kg. Part 2 includes dose expansion in 2L/2L+ large B-cell lymphoma in the ZYNLONTA plus glofitamab arm at dose levels determined from Part 1 (120 µg/kg and 150 µg/kg of ZYNLONTA plus the approved dosing of glofitamab). Primary endpoints of the study include safety and tolerability. Secondary efficacy endpoints include ORR, DOR, CRR, PFS, RFS, and OS as well as pharmacokinetics and immunogenicity. For more information about the LOTIS-7 trial, visit (NCT04970901). About ZYNLONTA® ZYNLONTA® is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. The potent payload binds to DNA minor groove with little distortion, remaining less visible to DNA repair mechanisms. This ultimately results in cell cycle arrest and tumor cell death. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily pre-treated patients (median three prior lines of therapy) with difficult-to-treat disease, including patients who did not respond to first-line therapy, patients refractory to all prior lines of therapy, patients with double/triple hit genetics and patients who had stem cell transplant and CAR-T therapy prior to their treatment with ZYNLONTA. This indication is approved by the FDA under accelerated approval and in the European Union under conditional approval based on overall response rate and continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Please see full prescribing information including important safety information about ZYNLONTA at ZYNLONTA is also being evaluated as a therapeutic option in combination studies in other B-cell malignancies and earlier lines of therapy. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company helping to improve the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development. ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London and New Jersey. For more information, please visit and follow the Company on LinkedIn. ZYNLONTA® is a registered trademark of ADC Therapeutics SA. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential of ZYNLONTA® in combination with the bispecific antibody glofitamab, including the reproducibility and durability of any favorable results initially seen in patients dosed to date, and the Company's research, development and regulatory plans, including the timing and results of clinical trials and the timing and outcome of regulatory submissions. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: whether future LOTIS-7 clinical trial results will be consistent with or different from the LOTIS-7 data presented at EHA and ICML and future compendia and regulatory strategy and opportunity; the expected cash runway into mid-2026 the Company's ability to grow ZYNLONTA® revenue in the United States; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company's or its partners' research and development projects or clinical trials including LOTIS 5 and 7, as well as early research in certain solid tumors with different targets, linkers and payloads; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. CONTACTS:Investor RelationsMarcy GrahamADC 650-667-6450 Media RelationsNicole RileyADC 862-926-9040 View original content to download multimedia: SOURCE ADC Therapeutics SA Sign in to access your portfolio
Yahoo
37 minutes ago
- Yahoo
Liquid Biopsy Markets, 2029 - Exploring Screening, Diagnostic, and Therapy Selection Opportunities
Explore the evolving landscape of cancer diagnostics with our comprehensive report, analyzing screening, diagnostic, and therapy selection markets. Discover potential growth by cancer type and region, with insights into circulating tumor cells, cell-free DNA, and exosomes. Forecasts and valuations empower informed decisions. Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Liquid Biopsy Markets by Cancer, Usage, Biomarker, Place, & Product with Price and Volume Outlook, Including Executive and Consultant Guides 2025-2029" has been added to offering. Explore the dynamic landscape of the Screening, Diagnostic, Therapy Selection, Minimal Residual Disease, and Screening Market through our comprehensive report, which provides a detailed analysis of price and volume outlooks across different types of cancer. Discover the transformative advancements in cancer diagnostics, particularly the innovative use of in vitro blood testing to detect cancer DNA, paving the way for widespread cancer screening tests. This cutting-edge technology is advancing rapidly, outpacing market growth, and offers a less invasive alternative to traditional surgical biopsies, poised to revolutionize disease diagnosis and monitoring. The report delves into the growth phase of the market, offering insights into its substantial impact on the healthcare industry. It includes a five-year forecast of market size expansion, with detailed projections segmented by country, cancer type, and usage categories-ranging from screening, diagnosis, therapy selection, to recurrence monitoring. Our analysis provides a granular breakdown for 15 countries and 4 regions, alongside specific insights on cancers such as Lung, Breast, Colorectal, Prostate, Cervical, and others. It also explores opportunities and challenges within screening, early detection, diagnostic, therapy monitoring, and recurrence monitoring realms, equipping stakeholders with essential knowledge for making informed investment decisions and accurate market valuations. Capitalizing on the exhaustive market intelligence contained within, this report empowers decision-makers to confidently navigate the evolving cancer diagnostics landscape, leveraging unprecedented technological advancements to enhance patient outcomes and streamline healthcare processes. Key Topics Covered: 1 Market Guides1.1 Liquid Biopsy Market - Strategic Situation Analysis1.2 Guide for Executives, Marketing, Sales, and Business Development Staff1.3 Guide for Management Consultants and Investment Advisors1.4 Impact of Artificial Intelligence on Liquid Biopsy Market2 Introduction and Market Definition2.1 What is Liquid Biopsy?2.2 The Sequencing Revolution2.3 Market Definition2.4 Methodology2.5 Perspective: Healthcare and the IVD Industry3 Market Overview3.1 Players in a Dynamic Market3.2 Using Biopsies3.3 Biopsy Sites3.4 The Situation Today - Biopsy Analysis3.5 Evidence of Cancer - Liquid Biopsy Technology3.6 Cancer Treatment Protocol Under Siege3.7 Structure of Industry Plays a Part4 Market Trends4.1 Factors Driving Growth4.1.1 Non-Invasive Game Changer4.1.2 Lower Cost4.1.3 Greater Accuracy4.1.4 Wide Range of Potential Uses4.1.5 Aging Population4.2 Factors Limiting Growth4.2.1 Lower prices4.2.2 Lack of Standards4.2.3 Protocol Resistance4.2.4 Initial Adoption Cost4.2.5 Conclusion4.3 Instrumentation and Automation4.3.1 Instruments Key to Market Share4.3.2 Bioinformatics Plays a Role4.4 Diagnostic Technology Development4.4.1 Next Generation Sequencing Fuels a Revolution4.4.2 Impact of NGS on pricing4.4.3 Pharmacogenomics Blurs Diagnosis and Treatment4.4.4 CGES Testing, A Brave New World4.4.5 Biochips/Giant magneto resistance based assay5 Liquid Biopsy Recent Developments5.1 Recent Developments - Importance and How to Use This Section5.1.1 Importance of These Developments5.1.2 How to Use This Section5.2 Liquid Biopsy Firm QCDx Closes Financing5.3 LabCorp Launches Liquid Biopsy5.4 OncoHelix, AstraZeneca to Provide Prostate Cancer Liquid Biopsy Testing5.5 Liquid Biopsy Developer Oxford Cancer Analytics Raises $11M5.6 GeneCentric Therapeutics Launches ExpressCT Liquid Biopsy Platform5.7 Syantra Closes Financing5.8 Concerns Over Grail Test Effectiveness5.9 Guardant Health Sues Tempus for Patent Infringement5.10 Delfi Dx Liquid Biopsy Technology Shows Promise5.11 Thermo Fisher Scientific, Bayer to Develop NGS-Based CDx5.12 Grail Details TBE Method for Cancer Monitoring5.13 Naveris HPV Liquid Biopsy Test Gets Medicare Coverage5.14 Personalis NeXT Personal Dx Early-Access Program5.15 Liquid Biopsy Shortens Time to Treatment5.16 Guardant Health MRD Test Garners Coverage5.17 IMBdx, AstraZeneca Expand Prostate Cancer Liquid Biopsy Partnership5.18 FoundationOne Liquid Biopsy Assay Gets FDA OK as Companion Diagnostic5.19 Epic Sciences Raises $24M for Breast Cancer Liquid Biopsy Test5.20 GenoMe Diagnostics Preparing DPCR-Based Ovarian Cancer Test5.21 Sophia Genetics to Commercialize Liquid Biopsy Test5.22 Agilent, Qiagen Nab FDA Approvals for Lung Cancer Treatment CDx5.23 Liquid Biopsy Startup Haystack Oncology Raises $56M5.24 Hedera Dx to Launch Liquid Biopsy Streamlined Platform5.25 PamGene Expanding Liquid Biopsy Assays5.26 Liquid Biopsy Firm Hedera Dx Raises €14M5.27 MDxHealth Plans One-Stop Shop for Prostate Cancer Dx5.28 Precision Oncology Dx Access Varies Widely in Europe5.29 Extracellular Vesicles Show Promise as Early-Stage Cancer Diagnostic5.30 Predicine Receives CE Mark for Blood and Urine Liquid Biopsy5.31 BillionToOne Launches First Liquid Biopsy Products5.32 Dxcover Advances Multicancer Detection Platform5.33 CorePath Laboratories, Cizzle Biotechnology Partner on Lung Cancer Blood Test5.34 Illumina Sues Guardant Health Over Patents5.35 Invitae to Expand Cancer Testing Portfolio5.36 Cancer Centre, Inivata Partner on Clinical Liquid Biopsy Studies5.37 IVBH Bio Takes Aim at With Liquid Biopsy Incubator5.38 Molecular Health, Eone-Diagnomics Ink Liquid Biopsy Partnership5.39 Delfi Diagnostics Looks To Fragmentation-Based Liquid Biopsy Tech5.40 BillionToOne Adapting Fetal Dx Tech for Liquid Biopsy5.41 EDGC to Expand Liquid Biopsy Space With Cell-Free DNA Platform5.42 Liquid Biopsy Startup BioCaptiva Raises £1M in Seed Funding5.43 Agilent Enters Liquid Biopsy Market with Resolution Biosciences Acquisition5.44 Bio-Techne to Acquire Asuragen for up to $320M5.45 Personalis Broadens Liquid Biopsy Offering5.46 Exact Sciences to Offer End-to-End Cancer Testing With Ashion Acquisition5.47 Delfi Diagnostics Plans Multi-Cancer Screening Test5.48 Menarini's CellSearch Shows Potential to Predict Breast Cancer Prognosis, Treatment Response5.49 Liquid Biopsy NGS Panels - Diverse Test Claims5.50 CMS Colon Cancer Screening Memo Bodes Well for Assays5.51 Natera Liquid Biopsy Test Coverage to Expand5.52 Freenome Closes Financing to Support Early Cancer Detection Trial5.53 C$2.6M Liquid Biopsy Initiative5.54 NeoGenomics, Inivata Partner for Lung Cancer Liquid Biopsy5.55 Liquid Biopsy Shows Promise as Screen for Cancers5.56 Inivata launches RaDaRT for the detection of residual disease and recurrence5.57 Liquid Biopsy Assay Detects 50+ Types of Cancer5.58 Liquid Biopsy Study Confirms Concordance with Tissue Biopsy6 Profiles of Key Players6.1 Admera Health, LLC6.2 Abbott Laboratories6.3 AccuraGen Inc.6.4 Acuamark Diagnostics6.5 Agilent6.6 Amoy Diagnostics Co., Ltd.6.7 Anchor Dx6.8 ANGLE plc6.9 Applied DNA Sciences6.10 ARUP Laboratories6.11 AVIVA Systems Biology6.12 Baylor Miraca Genetics Laboratories6.13 Beckman Coulter Diagnostics (Danaher)6.14 Becton, Dickinson and Company6.15 Berkley Lights6.16 BGI Genomics Co. Ltd6.17 BillionToOne6.18 Bioarray Genetics6.19 Biocartis6.20 Biocept, Inc.6.21 Biodesix Inc.6.22 BioFluidica6.23 Biolidics Ltd6.24 bioMerieux Diagnostics6.25 Bioneer Corporation6.26 Bio-Rad Laboratories, Inc6.27 Bio-Techne6.28 Bioview6.29 Burning Rock6.30 Cardiff Oncology6.31 CareDx6.32 Caris Molecular Diagnostics6.33 CellCarta6.34 CellMax Life6.35 Cepheid (Danaher)6.36 Circulogene6.37 Cizzle Biotech6.38 Clearbridge Biomedics6.39 Clinical Genomics6.40 Cytolumina Technologies Corp.6.41 Datar Cancer Genetics Limited6.42 Diagnologix LLC6.43 Dxcover6.44 Element Biosciences6.45 Enzo Biochem6.46 Epic Sciences6.47 Epigenomics AG6.48 Eurofins Scientific6.49 Exact Sciences6.50 Fluxion Biosciences (Cell Microsystems)6.51 Freenome6.52 Fyr Diagnostics6.53 GeneFirst Ltd.6.54 Genetron Holdings6.55 GILUPI Nanomedizin6.56 Guardant Health6.57 HansaBiomed6.58 Haystack Oncology (Quest Dx)6.59 iCellate6.60 ICON PLC6.61 Illumina6.62 Incell Dx6.63 Inivata6.64 INOVIQ6.65 Invitae Corporation6.66 J&J Innovative Medicine6.67 Lucence Health6.68 Lunglife AI Inc6.69 MDNA Life SCIENCES, Inc.6.70 MDx Health6.71 Menarini Silicon Biosystems6.72 Mesa Laboratories, Inc.6.73 Millipore Sigma6.74 Miltenyi Biotec6.75 miR Scientific6.76 Myriad Genetics6.77 Nanostring6.78 NantHealth, Inc.6.79 Natera6.80 NeoGenomics6.81 Novogene6.82 On-Chip Biotechnologies6.83 Oncocyte6.84 OncoDNA6.85 Oncimmune6.86 Oxford Nanopore Technologies6.87 PamGene6.88 Panagene6.89 Personalis6.90 PGDx (Labcorp)6.91 PrecisionMed6.92 Predicine6.93 Predictive Oncology6.94 Prenetics6.95 Promega6.96 Qiagen6.97 Rarecells SAS6.98 RareCyte6.99 Revvity6.100 Roche Diagnostics6.101 Saga Diagnostics6.102 Screencell6.103 Siemens Healthineers6.104 simfo GmbH6.105 Singlera Genomics Inc.6.106 Singular Genomics6.107 Standard BioTools6.108 Stilla Technologies6.109 Superfluid Dx6.110 Sysmex Inostics6.111 Tempus Labs, Inc.6.112 Thermo Fisher Scientific6.113 Todos Medical6.114 Ultima Genomics6.115 Veracyte6.116 VolitionRX6.117 Vortex Biosciences7 The Global Market for Liquid Biopsy Diagnostics7.1 Global Market Overview by Country7.2 Global Market by Cancer - Overview7.3 Global Market by Usage - Overview7.4 Global Market by Place - Overview7.5 Global Market by Marker - Overview7.6 Global Market by Product - Overview8 Global Liquid Biopsy Diagnostic Markets - By Cancer8.1 Breast8.2 Colorectal8.3 Cervical8.4 Lung8.5 Prostate9 Global Liquid Biopsy Diagnostic Markets - by Usage9.1 Screening9.3 Diagnostic9.4 Therapy9.5 Monitor10 Global Liquid Biopsy Diagnostic Markets - by Place10.1 Hospital Lab10.2 Lab Service10.3 Lab Outpatient11 Global Liquid Biopsy Diagnostic Markets - by Marker11.1 Circulating Tumor Cell11.2 Cell Free DNA11.3 Vesicle12 Global Liquid Biopsy Diagnostic Markets - by Product12.1 Kits12.2 Instruments12.3 Service13 Appendices13.1 Growth of Approved IVD Test Menu13.2 Growth of Approved Average IVD Test Fee13.3 The Most Used IVD Assays13.4 The Highest Grossing Assays13.5 Laboratory Fees Schedule For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
